NIKKEI 225
27,666.98 +148.73 (+0.54%) HANG SENG
20,162.65 +378.00 (+1.91%) CRUDE OIL
73.54 +0.34 (+0.46%) GOLD FUTURES
1,967.90 -5.60 (-0.28%) DOW
32,394.25 -37.83 (-0.12%) Bitcoin GBP
22,220.63 +343.36 (+1.57%)
Sanofi (0A2V.L)
| Previous close | 50.07 |
| Open | 49.18 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 49.18 - 49.28 |
| 52-week range | 49.18 - 49.28 |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | 0.39 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial
Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial First and only biologic to demonstrate clinically meaningful and statistically significant reduction (30%) in exacerbations compared to placeboFirst and only biologic to show rapid and significant improvement in lung function (160 mL in FEV1) compared to placebo (77 mL in FEV1) First and only biologic to demonstrate significant improvements in quality of life
- Globe Newswire
Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis
Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis Approximately seven times as many patients aged 6 months to 5 years with severe atopic dermatitis treated with Dupixent experienced clear or almost clear skin and reduced overall disease severity compared to placeboPatients treated with Dupixent achieved rapid itch reduction as early as three weeks after start of therapy, with significant
- Globe Newswire
Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis
Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis More than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeksNearly four times as many patients on Dupixent saw a clinically meaningful reduction of itch, with improvements seen as early as one week Paris and Tarrytown, N.Y. March 18, 2023. Positive results from the clinical trial assessing Dup
